Tumor selective replication of Newcastle Disease Virus: Association with defects of tumor cells in antiviral defence

International Journal of Cancer

Volumn 119, Issue 2, 2006, Pages 328-338

  Fiola, Christoph ^a   Peeters, Ben ^b   Fournier, Philippe ^a   Arnold, Annette ^a   Bucur, Mariana ^a   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Antiviral proteins; Interferon ; Paramyxovirus; Tumor cells; Virus infection

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN KINASE R;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; ENZYME INDUCTION; FLUORESCENCE; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; NEWCASTLE DISEASE PARAMYXOVIRUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA SYNTHESIS; TRANSGENE; VIRUS GENOME; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

CELL LINE; CELL LINE, TUMOR; EIF-2 KINASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; GTP-BINDING PROTEINS; HUMANS; INTERFERON ALFA-2A; INTERFERON-BETA; NEWCASTLE DISEASE VIRUS; RECOMBINANT PROTEINS; RNA, VIRAL; TIME FACTORS; TRANSGENES; UP-REGULATION;

EID: 33745206950     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21821     Document Type: Article

References (51)

1. Hengel H, Koszinowski UH, Conzelmann KK. Viruses know it all: new insights into IFN networks. Trends Immunol 2005;26:396-401.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511.
3. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-64.
4. LeBon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002;14:432-6.
5. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, Nakaya T, Katsuki M, Noguchi S, Tanaka N, Taniguchi T. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β gene induction. Immunity 2000;13:539-48.
6. Taniguchi T, Takaoka A. The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002;14:111-16.
7. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002;21:85-93.
8. Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002;3:710-17.
9. Rebouillat D, Hovanessian AG. The human 2′, 5′-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res 1999;19:295-308.
10. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res 1997;17:503-24.
11. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5.
12. Norman KL, Lee PW. Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 2005;10:847-55.
13. Obuchi M, Fernandez M, Barber GN. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol 2003;77:8843-56.
14. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003;9:33-9.
15. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 1999;6:63-73.
16. Horvath CM. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem 2004;271:4621-8.
17. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, MDA-5, and inhibit its activation of the IFN-β promoter. Proc Natl Acad Sci USA 2004;101:17264-9.
18. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005;23:19-28.
19. Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther 2005;12:295-303.
20. Cassel WA, Murray DR, Olkowski ZL. Newcastle disease virus oncolysate in the management of stage III malignant melanoma. In: Sinkovics JG, Horvath JC, eds. Viral therapy of human cancer. New York: Marcel Dekker, 2005.577-689.
21. Lorence RM, Roberts MS, Groene WS, Rabin H. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Hernáiz Driever P, Rabkin SD, eds. Replication-competent viruses for cancer therapy. Monographs in virology, Vol. 22. Basel, Switzerland: Karger, 2001:160-82.
22. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
23. Fournier P, Zeng J, Schirrmacher V. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-α responses by viral protein or dsRNA. Int J Oncol 2003;23:673-80.
24. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14:129-35.
25. Termeer CC, Schirrmacher V, Brocker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 2000;7:316-23.
26. Washburn B, Weigand MA, Grosse-Wilde A, Janke M, Stahl H, Rieser E, Sprick MR, Schirrmacher V, Walczak H. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immun 2003;170:1814-21.
27. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 2002;21:685-94.
28. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005;54:587-98.
29. Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Hacker B, Schumacher M, Schirrmacher V. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J Clin Oncol 1997;15:1354.
30. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V, Herold-Mende C. Anti-tumor vaccination with HNSCC with autologous virus-modified tumor cells. Cancer Res 2004;64:8057-61.
31. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, Schuele-Freyer R, Kremer P, Ranaie G, Matejic D, Bauer H, Kiessling M, et al. Anti-tumor vaccination of patients with glioblastoma multiforme in a case-control study: feasibility, safety and clinical benefit. J Clin Oncol 2004;22:4272-81.
32. Balachandran S, Barber GN. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004;5:51-65.
33. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κ B by toll-like receptor. Nature 2001;413:732.
34. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, Barber GN. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity 2000;13:129-41.
35. Reichelt M, Stertz S, Krijnse-Locker J, Haller O, Kochs G. Missorting of LaCrosse virus nucleocapsid protein by the interferon-induced MxA GTPase involves smooth ER membranes. Traffic 2004;5:772-84.
36. Kochs G, Haener M, Aebi U, Haller O. Self-assembly of human MxA GTPase into highly ordered dynamin-like oligomers. J Biol Chem 2002;277:14172-6.
37. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31.
38. Edgil D, Harris E. End-to-end communication in the modulation of translation by mammalian RNA viruses. Virus Res 2005; [epub ahead of print] Doi:10.1016/j.virusres.2005.10.012
39. Savinova O, Joshi B, Jagus R. Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells. Int J Biochem Cell Biol 1999;31:175-89.
40. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, Collins C, Gray JW, Diebold J, Demetrick DJ, Lee JM. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-5.
41. Barber GN. VSV-tumor selective replication and protein translation. Oncogene 2005;24:7710-19.
42. Norman KL, Hirasawa K, Yang AD, Shields MA, Lee PW. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004;101:11099-104.
43. Lingel A, Simon B, Izaurralde E, Sattler M. The structure of the flock house virus B2 protein, a viral suppressor of RNA interference, shows a novel mode of double-stranded RNA recognition. EMBO rep 2005;6:1149-55.
44. Zeng J, Fournier P, Schirrmacher V. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int J Oncol 2004;25:293-302.
45. Asada T. Treatment of human cancer with mumps virus. Cancer 1974;34:1907-28.
46. Grote D, Russell SJ, Comu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97:3746-54.
47. Farassati F, Yang AD, Lee PWK. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001;3:745-50.
48. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johston RN, Janowska-Wieczorek A, Lee PWK, Kossakowska AE. Reovirus therapy of lymphoid malignancies. Blood 2002;100:4146-53.
49. Davis JJ, Fang B. Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 2005;7:1380-9.
50. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002;9:961-6.
51. Mohr I. To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 2005;24:7697-709.